Opioid Withdrawal and Medications for Opioid Use Disorder in Custody

Scope and warning#

This page addresses opioid withdrawal and access to MOUD — methadone, buprenorphine and, where relevant, naltrexone — in California county jails, including continuation of a community prescription, initiation of treatment in custody, and release planning. Alcohol and benzodiazepine withdrawal, sobering cells and the Title 15 detoxification rule are in Roadmap 060; disability law in custody generally, including accommodations unrelated to MOUD, is Roadmap 068; medication continuity generally is Roadmap 056; deaths are Roadmaps 064 and 065; refusal and informed consent are Roadmap 072.

The doctrinal center of MOUD-access litigation — the decisions granting injunctions requiring jails to provide MOUD — comes largely from federal courts outside the Ninth Circuit, decided at the preliminary-injunction stage. This page grades those decisions as persuasive, not binding, and identifies the Ninth Circuit principle that most constrains disability-law claims about treatment. Clinical statements are attributed and stated at description level; they are not a clinical standard of care, which must come from a qualified expert (Roadmap 074). This page uses role vocabulary — patient, detainee, prisoner, personal representative, successor in interest, heir — to describe who may act. Nothing here is legal advice.

The factual situation this roadmap addresses#

A generic hypothetical. A 34-year-old woman has received daily methadone from a licensed narcotic treatment program for two years. She is arrested on a warrant on a Thursday night and held before trial in a county jail. At intake she gives the screening nurse her clinic's name and her daily dose, and the nurse records both. Verification with the clinic is not completed before the weekend. She is placed on a withdrawal protocol with symptomatic medications only. By the third day she is vomiting, has diarrhea and cannot keep fluids down; nurses record rising withdrawal scores. She submits two sick-call requests and a grievance asking for her methadone. A written response states that "methadone is not provided at this facility." On the fifth day she is taken to an emergency department for dehydration and returned the same night with instructions to "consider resumption of opioid agonist therapy." She is released after three weeks without a dose, a prescription or a referral, and some days later is hospitalized after a nonfatal overdose. Health services in the jail are provided under a county contract by a private correctional health care company. Every person and fact here is invented.

Governing law#

The clinical and public-health frame: the federal guidelines and the data

The Bureau of Justice Assistance and National Institute of Corrections guidelines (AR-060-G01) are the most specific federal statement on jail withdrawal management. As read on the official host, they provide that "Verified medications (including medications for OUD) should be continued" (Recommendation G-4); that "Effective management of opioid withdrawal involves initiation of long-term buprenorphine or methadone"; that "Opioid withdrawal management without ongoing pharmacotherapy does not treat the underlying OUD"; that "Custody staff should be alert to potential opioid withdrawal signs and symptoms that begin within 72 hours" (G-10); and, in Table G-2, that patients at risk of opioid withdrawal who appear well should be monitored "at least every 4 hours for the first 72 hours from arrival to facility," with a Clinical Opiate Withdrawal Scale (COWS) score of 3 or more prompting clinical assessment. They state that their recommendations "do not supersede any federal, state, local, or tribal regulations." Grade: Documented report (federal agency guidance), relevant as evidence of recognized practice (Roadmap 088).

The Bureau of Justice Statistics reported that 63 percent of sentenced jail inmates met criteria for drug dependence or abuse in 2007–2009, compared with about 5 percent of the adult general population; that regular heroin or opiate use among jail inmates "increased from 12% in 2002 to 19% during 2007-09"; and that among those meeting the criteria, 19 percent of jail inmates had participated in a drug treatment program since admission (Drug Use, Dependence, and Abuse Among State Prisoners and Jail Inmates, 2007–2009, NCJ 250546; AR-061-E01). Its mortality series reports that intoxication deaths in local jails rose from 6 to 26 per 100,000 between 2000 and 2019, with a median of one day in custody before death (AR-060-E01). Those figures predate the period in which fentanyl came to dominate the illicit opioid supply, and no more recent federal series was opened for this page; they document the scale of the population at risk, not anything about any facility. Grade: Documented report.

Constitutional standards applied to withdrawal and MOUD

A detainee's claim that withdrawal was mismanaged, or that MOUD was withheld, is governed in the Ninth Circuit by the four-element objective standard of Gordon v. County of Orange, 888 F.3d 1118 (9th Cir. 2018) (AR-0961-C01), derived from Castro v. County of Los Angeles (AR-055-C01) and Kingsley v. Hendrickson (AR-059-C03): an intentional decision regarding medical care; a substantial risk of serious harm; a failure to take reasonable available measures that a reasonable official would have appreciated were needed; and causation, with conduct that is more than negligent — "something akin to reckless disregard." A sentenced prisoner's claim is governed by the Eighth Amendment's subjective deliberate-indifference standard (Estelle v. Gamble, AR-0961-C02; Farmer v. Brennan, AR-0961-C03), under which a difference of medical opinion is not enough unless the chosen course was medically unacceptable and chosen in conscious disregard of an excessive risk (Toguchi v. Chung, AR-057-C02). Roadmaps 042 and 043 develop both.

Two features of MOUD claims shape the constitutional analysis. First, a refusal to continue a verified prescription is a decision of a different kind from a choice among treatments: the question is whether the decision was a medical judgment about this patient or the application of a rule that excluded the treatment without regard to the patient. In Pesce v. Coppinger, No. 18-11972-DJC (D. Mass. Nov. 26, 2018) (AR-061-C01), a federal district court granting a preliminary injunction found the plaintiff "likely to succeed on the merits of his Eighth Amendment claim," describing the defendants as having "implemented a blanket policy prohibiting the use of methadone treatment," noting his allegation that the course of treatment ignored his physician's recommendations, and stating that "Defendants here have not given any consideration to Pesce's specific medical needs." That decision is persuasive only, preliminary, and from another circuit. Grade: Unsettled/split. Second, entity liability requires the entity's own policy or custom (Monell, AR-0961-C04; Tsao, AR-0961-C08), and a written rule excluding a class of medications is the paradigm of an express policy — which makes the provenance of any such rule, and the entity that adopted it, the first factual question (Roadmaps 047 and 049).

Disability law: ADA Title II and Section 504

The statutes. Title II provides that "no qualified individual with a disability shall, by reason of such disability, be excluded from participation in or be denied the benefits of the services, programs, or activities of a public entity, or be subjected to discrimination by any such entity" (42 U.S.C. § 12132; AR-061-F01). "Public entity" includes any local government and its departments and agencies (42 U.S.C. § 12131; AR-068-F01). State prisons "fall squarely within the statutory definition of 'public entity,'" and the Supreme Court noted that prisons provide "medical 'services'" (Pennsylvania Dep't of Corrections v. Yeskey, 524 U.S. 206, 210 (1998); AR-068-C01). Section 504 of the Rehabilitation Act provides that no otherwise qualified individual with a disability "shall, solely by reason of her or his disability, be excluded from the participation in, be denied the benefits of, or be subjected to discrimination under any program or activity receiving Federal financial assistance," and defines "program or activity" to include "all of the operations of" a department or agency of a local government (29 U.S.C. § 794(a), (b)(1)(A); AR-061-F04). Note the different causation phrasing: "by reason of" in Title II; "solely by reason of" in Section 504.

Opioid use disorder as a disability; the illegal-use exclusion. The Department of Justice's Title II regulation lists "drug addiction, and alcoholism" among impairments (28 C.F.R. § 35.108(b)(2); AR-060-R01). The statute excludes from protection "an individual who is currently engaging in the illegal use of drugs, when the covered entity acts on the basis of such use," but does not exclude a person who "is participating in a supervised rehabilitation program" and is no longer engaging in illegal use, and the term "illegal use of drugs" "does not include the use of a drug taken under supervision" by a licensed health care professional (42 U.S.C. § 12210(a), (b), (d)(1); AR-061-F02). Two further provisions matter in jails. First, the statute provides that an individual shall not be denied health services, or services provided in connection with drug rehabilitation, "on the basis of the current illegal use of drugs" if otherwise entitled (§ 12210(c)); the regulation states the rule in full: "A public entity shall not deny health services, or services provided in connection with drug rehabilitation, to an individual on the basis of that individual's current illegal use of drugs, if the individual is otherwise entitled to such services" (28 C.F.R. § 35.131(b)(1); AR-068-R07). Second, a person taking methadone or buprenorphine as prescribed is ordinarily not, for that reason, engaged in illegal drug use (an analytical inference from § 12210(d)(1)). Grade: Settled (statute and regulation text); Analytical inference as to the second point.

Jails, contractors and the regulation. The Title II regulation for detention facilities "applies to public entities that are responsible for the operation or management of adult and juvenile justice jails, detention and correctional facilities ... either directly or through contractual, licensing, or other arrangements with public or private entities, in whole or in part, including private correctional facilities" (28 C.F.R. § 35.152(a); AR-055-R01). The general prohibitions reach discrimination whether committed directly or through contractual or other arrangements (§ 35.130(b)(1); AR-061-R01); require reasonable modifications in policies, practices or procedures where necessary to avoid disability discrimination, unless the public entity shows that the modification "would fundamentally alter the nature of the service, program, or activity" (§ 35.130(b)(7)(i); AR-061-R01); forbid eligibility criteria that "screen out or tend to screen out" individuals with disabilities unless necessary (§ 35.130(b)(8); AR-061-R01); and permit legitimate safety requirements only if they are "based on actual risks, not on mere speculation, stereotypes, or generalizations" (§ 35.130(h); AR-061-R01). Grade: Settled (regulation text). A county cannot contract its Title II obligations away; whether a private contractor is itself directly liable under Title II is a distinct and contested question (Roadmap 068). Grade: Unsettled/split.

The Department of Justice's position. In The ADA and Opioid Use Disorder: Combating Discrimination Against People in Treatment or Recovery (Apr. 5, 2022) (AR-068-G01), the Civil Rights Division answers that people with opioid use disorder are "Typically, yes" protected "unless the individual is currently engaged in illegal drug use," lists jails and prisons among covered settings, and gives as an example a jail that does not allow incoming inmates to continue taking MOUD prescribed before their detention: "The jail's blanket policy prohibiting the use of MOUD would violate the ADA." The guidance states that it has "no legally binding effect" and "no force or effect of law." Grade: Documented report (agency interpretation; persuasive weight is for the court).

The injunction decisions. In Smith v. Aroostook County, No. 19-1340 (1st Cir. Apr. 30, 2019) (per curiam) (AR-068-C14), the First Circuit affirmed a preliminary injunction requiring a county jail to provide a woman her prescribed buprenorphine, finding "no abuse of discretion by the district court in its preliminary assessment of the issues." The court noted that the defendants said receipt of the medication "will depend on a case-by-case medical assessment" but did "not actually plan to obtain such an assessment from a qualified doctor prior to incarcerating" her, and recorded testimony that "forced and immediate withdrawal from buprenorphine will cause her painful symptoms." Pesce v. Coppinger (AR-061-C01) held a methadone patient "likely to succeed on the merits of his ADA claim." Neither decision binds a California court; both are preliminary; both turn on the absence of an individualized medical judgment. Grade: Unsettled/split (persuasive authority; no Ninth Circuit holding located).

The Ninth Circuit's medical-treatment/accommodation boundary, updated September 2026. Simmons v. Navajo County, 609 F.3d 1011 (9th Cir. 2010), rejects an ADA theory that merely restates an allegation of inadequate medical treatment for the disability. But the published Adom v. California Department of Corrections and Rehabilitation, No. 24-4756 (9th Cir. Sept. 8, 2026), expressly explains that Simmons does not exempt all decisions involving medical personnel or medical judgment from disability-accommodation review. The accommodation sought, access to services, notice, alternatives, and discriminatory denial matter. Adom concerned incontinence supplies and mobility-related limitations, not methadone, buprenorphine, or a county jail; applying its distinction to MOUD is reasoned analogy rather than an on-point MOUD holding. A plaintiff must still identify an ADA-protected denial or inadequate modification, not simply prefer another medical regimen. Grade: Published controlling Ninth Circuit principles; proposed MOUD application fact-dependent.

Damages under disability law (2026 correction). For compensatory damages under Title II and Section 504, the Ninth Circuit requires intentional discrimination established by deliberate indifference to a substantially likely federal-rights violation, not ordinary negligence (Duvall v. County of Kitsap, 260 F.3d 1124; Updike v. Multnomah County, 870 F.3d 939). Barnes v. Gorman precludes private-action punitive damages under Title II and Section 504. Cummings v. Premier Rehab Keller, 596 U.S. 212 (2022), barred emotional-distress damages under the Rehabilitation Act; critically, the Ninth Circuit extended that bar to Title II in published Payan v. Los Angeles Community College District, 169 F.4th 971 (9th Cir. Mar. 11, 2026). Payan did not eliminate all compensatory remedies: factually proved non-emotional losses may remain available. Do not equate a diagnosis or discomfort with independently recoverable emotional damages under these statutes. Injunctions, fees, Article III standing, and state immunity follow separate rules; United States v. Georgia, 546 U.S. 151 (2006), is a state-sovereign-immunity case, not a substitute for identifying a county or contractor defendant. Grade: Binding Ninth Circuit Title II emotional-distress holding; other losses must be proved.

California law: claims, immunities and programs

Government Code § 855.8: addiction-related state immunity and limits. Section 855.8 protects qualifying public entities and employees for specified failure-to-diagnose/failure-to-prescribe injuries involving addiction or mental illness, but its statutory subdivisions also distinguish negligence after a public employee undertakes to prescribe and negligence in administering prescribed treatment. An alleged blanket refusal to prescribe, a clinically justified substitution, a botched ordered dose, and a failure to summon urgent care are different actions, with potentially different statutory treatment; do not assume that labeling every MOUD event “withdrawal” avoids immunity. The private-clinician inquiry is separate: status as a public employee is an evidentiary and legal classification, not established by county contract branding alone (Gov. Code § 810.2). Section 855.8 is not a general defense to an independently established federal § 1983 or Title II violation. Current official California codification was not authenticated in this run; statutory interpretation and application require counsel. Grade: Statutory text assessed from inherited/secondary reproductions; defendant-specific outcome unsettled.

The prisoner immunity, the duty to summon and negligence. The public entity's immunity for injuries to prisoners (Gov. Code § 844.6; AR-051-S02), its exception for failure to summon immediate medical care (§ 845.6; AR-051-S01), and the narrow California reading of § 845.6 (Watson, AR-051-C01; Castaneda, AR-054-C01) apply as described in Roadmap 060. Severe dehydration from unrelenting vomiting is the kind of serious and obvious condition for which custody staff's failure to summon care can matter; the choice whether to provide MOUD is not a § 845.6 question. Professional-negligence claims against health care providers proceed under the Medical Injury Compensation Reform Act framework (Code Civ. Proc. §§ 340.5, 364; Civ. Code § 3333.2; AR-069-S06, AR-096-S04, AR-0961-S03; Roadmap 066).

California MAT Grant Program: historical authority, not verified current authorization. The 2021 enactment of Penal Code article 6, including § 6047.1, authorized the BSCC Medication-Assisted Treatment Grant Program and described permitted grant uses, including jail MOUD staffing, take-home doses and contracts with narcotic treatment providers. Section 6047.4 expressly provided that the article remained effective only until January 1, 2026, and was repealed on that date. Treat its provisions as historical grant authority unless a later authenticated enactment establishes extension or replacement; no such later enactment was verified here. Past applications, budgets, grant awards, reports, and funding terms may still be relevant to facilities and periods when the program operated. The grant authorization itself never imposed universal MOUD prescribing obligations. The official California Legislature site returned access restrictions during this review; the repeal text was read in a dated third-party statutory reproduction, so 2026 current-code authentication remains open. Grade: Historical enactment text corroborated by 2024/2025 reproductions; no categorical finding about replacement programs.

Medi-Cal reentry and DHCS BHIN 25-034 (2025). DHCS's October 17, 2025 notice describes MAT/MOUD access for incarcerated patients and practical avenues for methadone, including registered narcotic-treatment-program services and courtesy dosing. It identifies three distinct regulatory avenues relevant to treatment in custody: incidental adjunct treatment in a hospital for an independent medical/surgical condition; the time-limited 21 C.F.R. § 1306.07(b) emergency dispensing pathway pending referral; and a separately requested, discretionary DEA exception under § 1307.03. Do not turn any avenue into a standing jail license, an unlimited three-day renewal, or an automatic right to dosing at an unprepared facility. The notice also describes CalAIM pre-release MAT readiness requirements; whether a specific facility participated, had a licensed provider, completed readiness, or had agreements enabling NTP dosing requires dated records. DHCS PDF text was indexed and inspected, but direct PDF image retrieval returned HTTP 403, so it is not labeled manually PDF-authenticated. Grade: State agency guidance with recorded access limitation; facility practice unproved.

California Title 15, scope and treatment implementation. The general detoxification framework, pharmaceutical management, and recommended postrelease referral provisions in title 15, §§ 1213, 1216 and 1210, respectively, remain relevant, but each provision must be tied to the facility type, the applicable version, the actor, and facts. Do not infer that a specific medication is statutorily mandated merely because withdrawal screening, licensed administration, or a treatment plan was required. Whether medication self-administration restrictions, controlled-substance storage, audit trails and outside NTP coordination were implemented requires logs and contracts. The official BSCC compilation was not successfully retrieved; the inherited summaries must be authenticated against official current regulations before publication. Grade: Inherited regulatory summary; current official authentication open.

How MOUD is delivered in a jail: the controlled-substance rules#

The defense that a medicine could not lawfully be provided requires a precise understanding of federal controlled-substance law, summarized here from the regulation and the DHCS notice.

Methadone: which pathway was actually available. Under 21 C.F.R. § 1306.07(a), maintenance/detoxification dispensing ordinarily requires appropriate narcotic-treatment-program registration; the provision is not a general authorization for ordinary jail practitioners to prescribe methadone for OUD. The 2023 DEA final rule amended § 1306.07(b) to allow a qualifying practitioner not separately registered as an NTP to dispense up to a three-day supply at one time while arranging treatment; the emergency course may not be renewed or extended, and dispensing is not interchangeable with writing an outpatient prescription. Section 1306.07(c) addresses authorized hospital care when narcotics are incidental to treatment of conditions other than addiction; admission to a jail is not automatically that exception. DHCS BHIN 25-034 also describes a distinct, discretionary DEA exception process under § 1307.03 and NTP-based dosing/courtesy dosing. A litigant must identify prescriber licensing, DEA/NTP authority, pharmacy and chain-of-custody rules, agreements, patient suitability and actual timing. An assertion that “no lawful methadone path existed” or “the three-day rule required continuation indefinitely” is not established by the regulatory text. Grade: DEA 2023 final rule directly verified on official Government Publishing Office host; 2026 DHCS operational guidance indexed with limited access.

Buprenorphine. DHCS BHIN 25-034 reports that a practitioner with the necessary current DEA registration can prescribe buprenorphine for OUD; this is analytically distinct from the special methadone NTP dosing pathways. Verify professional scope, patient assessment, prescription authority, pharmacy supply, administration logs, and facility policies rather than inferring from a general “controlled substance” classification that buprenorphine is prohibited. Jail pharmaceutical controls and diversion safeguards matter, but they must be applied to actual available alternatives and the individual record. Grade: DHCS guidance and clinical/application facts; no finding that any specific staff member was authorized to prescribe.

Naltrexone and other approaches. The federal guidelines state that naltrexone, another FDA-approved medication for OUD, "is not approved for withdrawal management purposes, does not relieve withdrawal symptoms, and may precipitate withdrawal" (AR-060-G01, Opioid Withdrawal Considerations; confirmed against the official PDF on QC review). Whether a facility's offer of a different medication, or of withdrawal management alone, was a reasonable medical judgment for a particular patient is an expert question.

Confidentiality of SUD records — Part 2 compliance changed in 2026. The statutory protections at 42 U.S.C. § 290dd-2 and implementing 42 C.F.R. Part 2 are not a universal label for every jail clinical note: first establish whether records originated in a federally assisted Part 2 program or are records to which its restrictions attach. HHS's February 2024 final rule required compliance by February 16, 2026. A qualifying Part 2 patient consent can now cover future treatment, payment, and health-care-operations disclosures, with permitted HIPAA-rule redisclosure by eligible recipients; separately maintained SUD counseling notes have stricter, separate-consent treatment. Use or disclosure in proceedings against the patient remains specially restricted and may require specific consent or a qualifying court order; a broad clinical TPO consent cannot be silently repurposed for adverse litigation. In emergencies or coordination calls, identify the actual Part 2 exception and minimum required records, not a categorical claim that written consent is always the only route. Ask about the program's status and permitted channels before disclosure; record dates and purposes. Grade: Directly inspected official HHS January 2026 fact sheet; full 2026 Part 2 codified text not independently line-by-line authenticated.

The disability claim and the medical-care claim compared#

The same episode can present a constitutional medical-care claim and a distinct discrimination/accommodation claim, but neither follows automatically from the other. For the pretrial constitutional claim, identify each defendant's intentional care decision, seriousness of the risk, available measures and causal harm under Gordon; for a sentenced person, prove the Eighth Amendment mental-state elements. A Title II theory ordinarily targets the responsible public entity and asks about disability-based denial of access or an inadequate reasonable modification; Section 504 adds federal-funding/recipient considerations. Under Adom (2026), the presence of medical review does not alone defeat an accommodation claim, while Simmons continues to reject treating every inadequate-medical-treatment complaint as an ADA violation. Damages demand the separate intentional-discrimination proof and permissible loss category.

For constitutional care, test contemporaneous intake and dosing records, medication verification, vitals, withdrawal scores, clinical alternatives, refusal documentation, and who could act. For Title II/Section 504, test actual access and requested modifications: whether the decision flowed from a blanket exclusion, what the entity knew, whether prescribed MOUD or an alternative was evaluated individually, and whether a purported safety or diversion rationale was supported by actual patient- and facility-specific facts. A documented individualized decision can be powerful defense evidence but is not dispositive solely because a clinician made it (Adom); an isolated grievance or inability to secure a dose does not by itself prove a categorical policy. The party invoking regulatory infeasibility should identify the specific methadone/buprenorphine regulatory path, decision date, clinician, and NTP arrangements.

Applying the law to the hypothetical#

The hypothetical woman is a pretrial detainee, so Gordon supplies the constitutional medical-care framework; the record does not establish liability merely because her methadone was interrupted. Ask whether the named clinic and dose could be verified lawfully through appropriate Part 2 processes, what options were clinically appropriate at that time, whether 21 C.F.R. § 1306.07(b), an NTP visit/courtesy dose, or a case-specific DEA exception was feasible and authorized, and whether repeated deterioration triggered escalation. A statement that methadone “is not provided” is evidence to investigate, not alone proof of a governing jail policy. For a Title II theory, distinguish denial of a modification from a documented patient-specific treatment judgment under Simmons and Adom. Under no circumstance infer a causal relationship to harm solely from COWS scores without qualified medical assessment.

The emergency-department visit and its instruction would raise a hospital-return question (Roadmap 054): what was received, entered and acted on. Custody staff's response to days of vomiting would raise the § 845.6 question for public employees. The release without a dose, prescription or referral would raise questions under Title 15 § 1210's release-referral provision and about causation for the later overdose — an event after custody that a defendant will say was caused by independent choices and circumstances, and that a plaintiff will say was a foreseeable consequence of loss of tolerance and interrupted treatment, a point on which expert evidence would be required (Roadmap 075). For any state-law claim against the county, § 855.8 would be raised against any theory resting on the failure to prescribe; the contractor's clinicians would face professional-negligence claims outside that immunity. Nothing in this paragraph states what the records would show or that any decision was unlawful.

A step-by-step approach#

1. If the person is in custody, send a written request to the facility and the health services provider identifying the prescriber or clinic, the medication and dose, and asking for verification and continuation; ask the clinic to call the facility; keep copies and times.
2. Ask the program which applicable 42 C.F.R. Part 2 disclosure pathway permits dose verification: a properly scoped patient consent for treatment/payment/operations, a legally applicable exception, or another qualified route. If consent is needed, obtain it in a compliant form for the correct disclosing program and recipient; do not assume a generic medical release authorizes SUD counseling notes or use of records against the patient. Log every attempted call, response, and disclosure rationale.
3. File a grievance asking for the medication and for any reasonable modification, and keep the response; for a person still confined, exhaustion is required before federal suit (Roadmap 080).
4. Request the person's own jail health record, including intake screen, withdrawal flowsheets, COWS scores, medication administration records and any MOUD-related notes (Health & Saf. Code § 123110; AR-057-S09).
5. Obtain the county's health services contract and any MOUD or MAT program documents, grant applications under Penal Code § 6047.1 and CalAIM readiness materials through public records requests (Roadmap 087).
6. Identify whether any written or unwritten rule restricted MOUD, who issued it, and when; preserve every written response that states a rule (Roadmap 049).
7. Build a chronology from last dose to release, with each verification attempt, each score, each request and each response (Worksheet 100).
8. Separate the claims: constitutional (by individual and by policy), disability law (by entity), state-law (by public employee, public entity and private provider) — and identify which procedural gates apply to each (Roadmaps 078, 079, 080 and 066).
9. Obtain expert review on withdrawal management, MOUD and causation, including any post-release event.
10. Check the actual corporate entity, bankruptcy case, debtor schedules, plan and injunction before asserting bankruptcy restrictions. Roadmaps 090–091 remain under namespace hold and cannot substitute for checked bankruptcy primary records. Assemble the attorney-ready file (Roadmap 009.1).

Elements of the claim#

Fourteenth Amendment (detainee) (Gordon): intentional decision regarding medical care; substantial risk of serious harm; failure to take reasonable available measures a reasonable official would have appreciated were needed, with conduct objectively unreasonable; causation.

Eighth Amendment (sentenced) (Estelle, Farmer): serious medical need; actual knowledge and disregard of an excessive risk; harm.

Entity liability under § 1983: underlying violation; policy, custom or practice of the entity; deliberate indifference for inaction or training theories; moving-force causation (Roadmap 047).

ADA Title II (Roadmap 068): a qualified individual with a disability; excluded from participation in, denied the benefits of, or otherwise discriminated against in a public entity's services, programs or activities; by reason of disability — including through a failure to make a reasonable modification; and, for damages, intentional discrimination shown by deliberate indifference (Duvall).

Section 504: the same in substance, with the program receiving federal financial assistance and "solely by reason of" causation.

Professional negligence: duty; breach of the professional standard of care, by expert proof; causation; damages (Roadmap 066).

Failure to summon (Gov. Code § 845.6): a public employee knew or had reason to know of the need for immediate medical care and failed to take reasonable action to summon it.

Do not allege a fact unless you have a good-faith factual basis for it. In particular, do not allege that a facility "bans" MOUD on the strength of rumor or a single verbal statement; obtain the written response, the policy or the contract term, or plead what is known and why.

Potentially relevant defendants#

Potential defendants must be identified by actor and legal capacity, not by brand. The public entity operating the jail may be a Title II defendant, while a § 1983 entity-policy claim requires a relevant policy/custom and causation; investigate whether the sheriff is a local or state policymaker for the function at issue. A private contracting health organization may be implicated in § 1983 policy/custom or state negligence theories only with proof of its actual contractual and operational role; Section 504 requires an appropriate recipient-of-federal-financial-assistance theory. Individual clinicians, screeners and custody officers require separate duty, state-action, mental-state and causation analysis. A treatment program or hospital is not automatically liable for a jail's verification failures. Confirm corporate formation, contract effective dates, employee/contractor status and debtor status from primary records before naming any Wellpath/CFMG affiliate.

Administrative prerequisites#

A person confined when suit is filed must exhaust available administrative remedies before bringing an action with respect to prison conditions under § 1983 or any other federal law (42 U.S.C. § 1997e(a); AR-096-F04; R1 AR-S608; Ross v. Blake, AR-0961-C09) — which on the statute's terms includes disability-law claims. State-law damages claims against a county require a presented government claim (Gov. Code §§ 910, 911.2, 945.4; AR-131-S01, AR-096-S01, AR-096-S02); § 1983 claims do not (Williams v. Horvath, R1 AR-C08); whether and how the claim-presentation requirement applies to federal disability-law claims is a counsel question (Roadmap 079). A professional-negligence action against a health care provider requires at least 90 days' notice of intention to sue (Code Civ. Proc. § 364; AR-096-S04). Bankruptcy-related prerequisites for any Wellpath debtor entity are in Roadmaps 090 and 091.

Limitation periods#

If the person died, the survival and wrongful-death rules of Code Civ. Proc. §§ 377.30, 377.60 and 366.1 also apply (Roadmap 065). This table states sources and triggers; it computes no date (Roadmaps 008 and 082).

Evidence and records to obtain#

Key: H presently has lawfully; R statutory request; D discovery or subpoena only; P potentially privileged or private; K someone else must preserve but need not produce voluntarily (Roadmap 007); X must not access, copy or remove.

• The person's own narcotic treatment program or prescriber records, including dosing history and any record of calls from the jail — R (patient request with written consent under 42 U.S.C. § 290dd-2(b)); these are federally protected records and should be handled as P in any later disclosure.
• Pharmacy dispensing records for buprenorphine — R.
• The jail health record: intake screen, COWS or other withdrawal scores, vital signs, medication administration records, practitioner orders, verification notes — R (Health & Saf. Code § 123110), then D with audit trail.
• Sick-call requests, grievances and written responses — H for copies the person kept; R/D for the facility's file.
• Emergency-department and hospital records — R.
• Any written MOUD or MAT policy, protocol, formulary restriction or contract term; any agreement with a narcotic treatment program; Penal Code § 6047.1 grant applications and reports; CalAIM readiness documents — public records request where held by the county (Roadmap 087), otherwise D.
• Custody housing records, observation logs and video for the withdrawal period — K, D.
• Staffing and on-call records; communications between nurses and practitioners — D.
• Quality-review or committee records concerning the event — P (Evid. Code § 1157; AR-032-S04).
• Other patients' MOUD records, used to show a categorical practice — P; only through counsel, de-identified and under protective order.
• The jail's health record system, the narcotic treatment program's systems, and any pharmacy or custody database — X.

Favorable and adverse facts#

Facts that tend to support a claim: a documented prescription or enrollment that the facility recorded at intake; verification not attempted or not completed for days; a written statement of a categorical rule against a class of MOUD; no individualized medical assessment before discontinuation; rising withdrawal scores without escalation; dehydration or other complications requiring hospital care; an emergency-department recommendation that was not acted on; release without a dose, prescription or referral despite a treatment plan; safety reasons stated in general terms rather than as actual risks.

Facts that tend to defeat a claim: verification attempted promptly and frustrated by the clinic's unavailability or the absence of consent; an individualized clinical decision, with reasons, to taper or substitute; documented diversion or misuse in custody, assessed individually; the person's refusal of offered medication, with informed-consent documentation (Roadmap 072); prompt treatment of complications; a facility pathway to MOUD that was in fact available and offered; a post-release event separated from custody by time and intervening circumstances.

Likely defenses#

Expect adversaries to argue that dosing changed for medically documented reasons rather than a disability exclusion (Simmons); the new Adom forecloses any shortcut that all medically reviewed accommodation denials are beyond ADA scrutiny. They may show no provider, NTP contract, verified order, dispensing authority, or feasible timely exception (DEA rules), documented overdose/diversion risk, alternate appropriate therapy, consent limitations (Part 2), or no causation. They may invoke § 855.8 for nonprescription, §§ 844.6/845.6 on state claims, limited PLRA remedies, late government claims, exhaustion, or lack of intentional discrimination. Defense exhibits should be tested against dated pharmacy, NTP, jail-health, contract and escalation records. A debtor injunction is a defense only upon authenticated identification of the covered legal entity, case, plan, orders and effective date; a Wellpath-branded document is insufficient.

The deep companions to Roadmap 133 for these defenses are Playbooks 141 (constitutional medical-care defenses) and 140 (accommodation defenses, including the opioid-use-disorder cases).

Causation#

Three causal questions recur. First, what harm did the withdrawal itself cause — the suffering of untreated withdrawal, dehydration, hospital care — and would continued MOUD or more aggressive management more likely than not have prevented it? Second, for a disability claim, was the denial of a service "by reason of" disability (Title II) or "solely by reason of" disability (Section 504) — a causation question about the reason for the decision, not about medical outcome. Third, for any event after release — relapse, overdose, death — what is the causal link between the interruption of treatment in custody and the later event, and what intervening causes will be argued? The evidence described in the injunction decisions (testimony in Smith that forced withdrawal would cause painful symptoms; the physician's opinion in Pesce that denying methadone would place the plaintiff at "a high risk of overdose and death upon his release") illustrates the kind of expert evidence a court weighs; it does not establish causation in any other case (Roadmap 075).

Damages and remedies#

Remedies depend on cause of action, defendant, individual status, incarceration status and proved loss (Roadmaps 076, 081, 096.2). Under § 1983, compensatory damages and properly supported individual-capacity punitive damages may be available; neither § 1983 nor Title II turns a county into a routine punitive-damages defendant. Under ADA Title II/Section 504, injunctive relief may be available where standing and other requirements are met, but damages require the Duvall deliberate-indifference/intent showing. Barnes bars punitive damages. **Emotional-distress damages are unavailable under both private Rehabilitation Act claims (Cummings) and Title II (Payan, 169 F.4th 971 (9th Cir. 2026)); eligible non-emotional proven economic or other compensable loss** cannot be dismissed categorically. Payan involved loss of educational opportunities; it did not decide which losses arise from jail MOUD interruption. The Prison Litigation Reform Act, Government Claims Act, state MICRA law and wrongful-death/survival rules can add different restrictions; each must be analyzed without double counting.

Discovery#

Organize discovery around the rule, patient record, available lawful supply path, and actor (Roadmaps 038, 084). Seek dated versions of prescribing policy, formulary, contract and NTP correspondence, DEA registration or discretionary-exception paperwork if any, pharmacy supply/dose transport and chain of custody, training, grievance responses, and facility CalAIM readiness documents if applicable; do not assume participation or infer a duty from a historic MAT grant. Seek full intake and withdrawal observations, attempts to verify doses, administration records and contemporaneous risk/alternative analyses with audit trail. Comparator records require lawful disclosure, minimum necessary access, de-identification or appropriate protective orders; Part 2 imposes additional limits when qualifying program records are involved, and separately maintained counseling notes and use against patients warrant separate review. Distinguish litigation preservation from voluntary production. Preserve exact entity/employee and bankruptcy-document provenance. Clinical peer-review confidentiality and Evidence Code § 1157 require separate legal analysis; no blanket assertion that all QA files are discoverable.

CFMG/Wellpath-specific relevance#

In a CFMG/Wellpath-related setting, determine which exact legal entity and contract supplied care during the incident, who adopted any MOUD restriction, which staff or NTP had dispensing authority, and whether historical grant or CalAIM steps actually occurred. The county's Title II obligations may encompass outsourced services under 28 C.F.R. § 35.152(a), but that principle does not identify a contractor's § 1983 policy or establish wrongdoing. Inherited R1 entries assert different bankruptcy treatment for “California Forensic Medical Group, Inc.” and “Wellpath CFMG, Inc.”; those are unverified investigative leads, not adjudicated facts in this manuscript. Original petitions, debtor schedules, confirmed plan, injunction, affiliates and the dated county contract must be compared before asserting either is a debtor or nondebtor, an alter ego, or a proper defendant. Roadmaps 090–091 remain on numbering hold and should not be used as an independently reconciled filing authority. No actual CFMG/Wellpath medication policy, injury, breach, contract attribution or liability is established here.

Primary authorities#

Related roadmaps#

007, 008, 009.1, 040, 041, 042, 043, 045, 046, 047, 049, 054, 055, 056, 060, 062, 064, 065, 066, 068, 072, 074, 075, 076, 077, 078, 079, 080, 081, 082, 083, 084, 085, 086, 087, 088, 090, 091, 096.2, 132, 133.

Companion worksheet#

Worksheet 109 (custody, medical, medication, referral, grievance and emergency records) for the clinical record and the requests; Worksheet 100 (chronology) from last community dose to release; Worksheet 110 (staffing, policies and training) for any MOUD rule and its provenance; Worksheet 114 (preservation and records distinction), with a column for federally protected treatment records. The dedicated companion is Worksheet 117 (Medication Continuity and Administration Worksheet), which can carry an MOUD-access record that captures the prescription, each verification attempt, each request and response, any stated rule and its source, and the release plan.

What this page cannot do#

It cannot say whether any facility had or has any MOUD policy, whether any decision was a medical judgment or a discriminatory rule, whether any person was harmed by any decision, or whether any claim exists or is timely. It cannot say whether persuasive decisions from other circuits would be followed by a court in California. It cannot substitute for addiction-medicine expertise or for counsel. It maps the law, the mechanics and the records so that those questions can be asked precisely.